Core Insights - Intelligent Bio Solutions Inc. (INBS) has formed a strategic manufacturing partnership with Syrma Johari MedTech to enhance its production capabilities and support its entry into the U.S. market in 2026 [1][3]. Group 1: Partnership Benefits - The partnership is expected to yield annual production cost savings exceeding 40%, leading to an anticipated improvement of approximately 20 percentage points in gross margin compared to previous manufacturing arrangements [2]. - Syrma Johari's manufacturing capacity is about four times that of INBS, enabling the company to efficiently meet anticipated demand as it scales its commercial operations [2]. Group 2: Supply Chain Resilience - This collaboration strengthens INBS' global manufacturing strategy by reducing reliance on a single supplier and enhancing supply chain resilience [3]. - The partnership broadens manufacturing capacity, ensures continuity, and creates flexibility in preparation for future demand across multiple regions [3]. Group 3: Syrma Johari's Capabilities - Syrma Johari has over 45 years of experience in medical device engineering and manufacturing, operating 14 manufacturing locations and four design and innovation centers globally [4]. - The company is certified to ISO 13485, MDSAP, FDA, TUV SUD, and GMP standards, ensuring high compliance and quality in medical device manufacturing [4]. Group 4: Production Efficiency - Syrma Johari's vertical integration and export-oriented model facilitate high-quality production while optimizing sourcing, tooling, testing, and logistics [5]. - The company is set to open a new medical-grade plastics manufacturing facility in India in January 2026, further enhancing its capabilities to meet global demand [5]. Group 5: Regulatory Support - Syrma Johari's extensive regulatory and quality-assurance capabilities align with INBS' global expansion plans, providing end-to-end quality systems and regulatory documentation support [6]. - This expertise will assist INBS in advancing its regulatory pathways and preparing for increased commercial activity worldwide [6]. Group 6: Strategic Importance - The partnership is viewed as a significant milestone for INBS, enhancing its supply chain and supporting future growth [7]. - Both companies express a strong alignment in innovation, quality, and long-term vision, indicating a commitment to scaling disruptive drug-screening technology [7][8].

Companies to leverage and collaborate on research and development, distribution, and regulatory expertise to accelerate global adoption of intelligent testing technologies Alliance positions INBS to enter the fast-growing consumer health market, broadening revenue opportunities beyond commercial screening NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutio ...

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“Intelligent Bio Solutions” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it will effect a 1-for-10 reverse split of its common stock, that will become effective at 11:59 pm (Eastern Time) on December 15, 2025. Trading of the Company's common stock on The Nasdaq Capital Market (“Nasdaq”) will continue, on a split-adjusted basis, with ...

Core Insights - Intelligent Bio Solutions Inc. will participate in the 21st Annual Emerging Growth Equity Conference hosted by Noble Capital Markets on December 2-3, 2025 [1] Company Overview - Intelligent Bio Solutions Inc. is a medical technology company focused on delivering intelligent, rapid, non-invasive testing solutions [4] - The company’s Intelligent Fingerprinting Drug Screening System utilizes fingerprint sweat analysis, aiming to revolutionize portable testing with potential applications in various fields [4] - The system is designed to be hygienic and cost-effective, screening for recent drug use, including opiates, cocaine, methamphetamine, and cannabis, with results available in under ten minutes [4] - Current customer segments outside the U.S. include construction, manufacturing, engineering, transport and logistics, mining, drug treatment organizations, and coroners [4] Conference Details - The conference will take place at Florida Atlantic University, Boca Raton, FL, with Intelligent Bio Solutions scheduled to present on December 3, 2025, at 11:00 a.m. Eastern Time [2] - A webcast recording of the presentation will be available on the company's investor relations website and Noble's website for 90 days post-event [2]

Core Insights - Intelligent Bio Solutions Inc. (INBS) is participating in the Noble Capital Markets' 21st Annual Emerging Growth Equity Conference on December 2-3, 2025, in Boca Raton, Florida [1][2] Company Overview - Intelligent Bio Solutions Inc. is a medical technology company focused on delivering intelligent, rapid, non-invasive testing solutions [4] - The company's Intelligent Fingerprinting Drug Screening System utilizes fingerprint sweat analysis, aiming to revolutionize portable testing with potential applications in various fields [4] - The system is designed to be hygienic and cost-effective, screening for recent drug use, including opiates, cocaine, methamphetamine, and cannabis, with sample collection in seconds and results in under ten minutes [4] - Current customer segments outside the U.S. include construction, manufacturing, engineering, transport and logistics, mining, drug treatment organizations, and coroners [4]

Core Insights - Intelligent Bio Solutions Inc. reported record quarterly revenue of $1.11 million, marking a 32% increase sequentially and a 28% increase year-over-year, primarily driven by consumable cartridge sales and customer base expansion [1][2][3] Financial Performance - The fiscal 2026 first quarter revenue reached $1,111,797, up 32% from the previous quarter and 28% from the same quarter last year [7] - Cartridge sales accounted for approximately 57.59% of total revenue, increasing from 51.1% in the prior year, indicating a strong recurring revenue model [7] - Gross profit margins improved by 690 basis points year-over-year to 46.6%, attributed to enhanced operational efficiency and a favorable product mix [2][7] Operational Highlights - The company added 33 new customer accounts during the quarter, bringing the total to 492 across more than 24 countries [7] - A significant contract was secured with a London public transport operator, covering 14 operational sites and over 4,400 staff, representing a major scale deployment [7] - The product portfolio was expanded with the introduction of the SmarTest® Patch, a continuous drug monitoring solution [7] Strategic Market Expansion - The company is focusing on strategic partnerships and international market expansion, positioning itself for continued growth [2][6] - A global distribution agreement was established with SMARTOX® to introduce the SmarTest Patch technology to markets outside the U.S. and Canada [7]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 001-39825 Intelligent Bio Solutions Inc. (Exact name of Registrant as specified in its Charter) Delaware 82-1512711 ...

Financial Results - Intelligent Bio Solutions Inc. announced preliminary, unaudited revenue results for the fiscal first quarter ended September 30, 2025[3]. - The press release detailing the financial results was issued on November 4, 2025[3]. Company Classification - The company is classified as an emerging growth company under the Securities Act of 1933[2].

Core Insights - Intelligent Bio Solutions Inc. achieved a record revenue of over $1 million for the fiscal first quarter ended September 30, 2025, marking a significant milestone for the company [2] - The company reported a revenue increase of approximately 32% sequentially and 28% year-over-year, indicating strong growth momentum [2][3] - Cartridge revenue rose approximately 43% year-over-year, while reader revenue increased by about 23% year-over-year, reflecting the effectiveness of the company's business model [2] Revenue Performance - The company has experienced three consecutive quarters of revenue growth, showcasing the strength of its razor-razorblade business model [2] - The anticipated revenue growth is attributed to an improved sales mix, with higher-margin consumables making up a larger share of total revenue [2] Company Overview - Intelligent Bio Solutions Inc. specializes in intelligent, rapid, non-invasive testing solutions, particularly through its Intelligent Fingerprinting Drug Screening System [4] - The technology is designed for quick sample collection and results, making it suitable for safety-critical industries such as construction, manufacturing, and transport [4]

Core Insights - Intelligent Bio Solutions Inc. reported a 50% increase in new customer accounts during the fiscal first quarter, totaling over 480 active accounts, indicating strong customer expansion and revenue momentum [1][3][4] Company Performance - The company added 33 new customer accounts in the fiscal first quarter ended September 30, 2025, compared to the same period last year [1] - Approximately 91% of new accounts were first-time adopters of the drug screening solution, while 9% were expansions within existing customer organizations [3] - The company aims to convert current momentum into sustained revenue growth and long-term value [3] Market Trends - The global drug screening market is projected to reach USD 17.1 billion by 2029, growing at a CAGR of 15%, driven by increasing regulatory focus on workplace safety and demand for non-invasive testing solutions [4] - Adoption of the Intelligent Fingerprinting Drug Screening System is broadening across various industries, reflecting its scalability and alignment with modern compliance standards [5] Sector Growth - Strongest growth in customer acquisition was noted in sectors such as maritime, transportation and logistics, electrical and electronic manufacturing, construction, and government administration [2] - Government administration is a newly entered sector, highlighting the expanding applicability of the company's solutions [2]